Monopar Therapeutics (MNPR) Long-Term Deferred Tax (2020 - 2022)

Monopar Therapeutics (MNPR) has 3 years of Long-Term Deferred Tax data on file, last reported at $11.1 million in Q4 2022.

• For the quarter ending Q4 2022, Long-Term Deferred Tax rose 219.77% year-over-year to $11.1 million; the trailing twelve-month figure through Dec 2022 stood at $11.1 million (up 219.77% YoY), and the FY2022 full-year result was $11.1 million, up 219.77% from the prior year.
• Long-Term Deferred Tax climbed to $11.1 million in Q4 2022, from $3.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $11.1 million in Q4 2022 to a low of $3.5 million in Q4 2021.
• A 3-year average of $6.6 million and a median of $5.2 million in 2020 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax sank 33.25% in 2021 and surged 219.77% in 2022, its largest moves.
• Tracing MNPR's Long-Term Deferred Tax over 3 years: stood at $5.2 million in 2020, then slumped by 33.25% to $3.5 million in 2021, then surged by 219.77% to $11.1 million in 2022.
• Business Quant data shows MNPR's Long-Term Deferred Tax at $11.1 million in Q4 2022, $3.5 million in Q4 2021, and $5.2 million in Q4 2020.